Email Us
View Reports

Hemophilia A Treatment Market

Hemophilia A Treatment Market Research Report 2022 | Market Size, Share and Outlook Analysis

  • ID : 74475665  |  
  • Published : Jan-2019  |  
  • Region : Global  |  
  • Pages : 100   |  
  • Publisher : Polaris Market Research

Hemophilia A Treatment Market Overview:

Hemophilia A patients have begun to shift from short acting to EHL factors and from on demand therapies to prophylactics. The increasing prevalent population of Hemophilia A and the rise in demand of the prophylactics treatments in developed markets will have a great impact on this market.

According to the US Centers for Disease Control and Prevention, hemophilia A occurs in 1 in 5,000 live male births. Hemophilia A is about four times as common as hemophilia B. The number of people with hemophilia in the United States is estimated to be about 20,000 individuals. Approximately 75% of people with hemophilia around the world still receive inadequate treatment or have no access to treatment.

What is the Size of Hemophilia A Treatment Market:

Hemophilia A Treatment Market Size was valued at USD 9.31 billion in 2016 and is expected to grow at a CAGR of 5.9% during the forecast period.

Geographical Analysis of Hemophilia A Treatment Market:

Research Cosmos expects that with the expected launch of the promising treatments, the market is expected to expand in Hemophilia A segment. The United States dominates the Hemophilia A treatment market followed by Europe 5 and Japan. The prophylaxis segments are predicted to be the fastest growing segment whereas the on-demand therapy segment is expected to contribute close to ~50% to the market during the forecast period. With the increase in the R&D investments and rising drug innovations in this field, the market is expected to significantly expand in the next five years.

RNA based therapeutics and curative gene therapies are rapidly progressing through clinical development and are seen as an attractive segment of this market.

Research Cosmos has provided the forecasts of the Global Hemophilia A Market from 2016-2022. The major segments which has been investigated in the global market from 2016-2022 are:

  • Market Analysis by Hemophilia A treatment

  • Market Analysis by Treatments/Marketed Drugs

  • Market Analysis by G7 countries

The Marketed Therapies undertaken in forecast from 2016-2022 are:

  • Afstyla Sales Forecast-2016-2022

  • Eloctate Sales Forecast-2016-2022

  • Hemlibra Sales Forecast-2016-2022
  • Kogenate FS Sales Forecast-2016-2022
  • Kovaltry Sales Forecast-2016-2022
  • Nuwiq Sales Forecast-2016-2022
  • Obizur Sales Forecast-2016-2022

The Major Indications in Hemophilia A Therapy area:

  • Prophylaxis-Market Forecast 2016-2022

  • On-demand therapy-Market Forecast 2016-2022

  • Inhibitor therapy- Market Forecast 2016-2022

The Market Forecast of Hemophilia A Treatment by G7 Countries (2016-2022):

  • United States- Market Forecast (2016-2022)

  • Germany- Market Forecast (2016-2022)

  • France-Market Forecast (2016-2022)
  • Italy- Market Forecast (2016-2022)
  • Spain- Market Forecast (2016-2022)
  • United Kingdom- Market Forecast (2016-2022)
  • Japan- Market Forecast (2016-2022)

Hemophilia A Treatment Market - By Regions:

  • North America

  • Europe

  • Asia Pacific
  • South America
  • Middle East & Africa

Leading Companies investigated in this Hemophilia A Treatment Market Report are:

  • CSL Behring

  • Shire

  • Bayer
  • Biogen
  • Genentech
  • Bioverativ
  • Alnylam Pharmaceuticals
  • Sanofi (Genzyme)
  • BioMarin Pharmaceutical
  • Hoffmann-La Roche
  • Sinocelltech Ltd.
  • Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
  • Octapharma
  • LFB USA, Inc.
  • Novo Nordisk A/S
  • Pfizer

Table of Contents:

1. Hemophilia A Treatment Market Summary

2. Hemophilia A Treatment Overview

2.1. Disease Definition

2.2. Hemophilia Types

2.2.1. Mild

2.2.2. Moderate

2.2.3. Severe

2.3. Disease Symptoms

3. Current Diagnosis Patterns

4. Treatment Patterns of Hemophilia A

4.1. Treatment Guidelines for Hemophilia A

5. Hemophilia A treatment Epidemiology -Prevalent Population & Segmentations

5.1. Prevalent Population Globally (2016-2022)

5.1.1. Mild Prevalent Cases (2016-2022)

5.1.2. Moderate Prevalent Cases (2016-2022)

5.1.3. Severe Prevalent Cases (2016-2022)

5.2. Prevalent Population in the United States (2016-2022)

5.2.1. Mild Prevalent Cases (2016-2022)

5.2.2. Moderate Prevalent Cases (2016-2022)

5.2.3. Severe Prevalent Cases (2016-2022)

5.3. Prevalent Population in Germany (2016-2022)

5.3.1. Mild Prevalent Cases (2016-2022)

5.3.2. Moderate Prevalent Cases (2016-2022)

5.3.3. Severe Prevalent Cases (2016-2022)

5.4. Prevalent Population in France (2016-2022)

5.4.1. Mild Prevalent Cases (2016-2022)

5.4.2. Moderate Prevalent Cases (2016-2022)

5.4.3. Severe Prevalent Cases (2016-2022)

5.5. Prevalent Population in Italy (2016-2022)

5.5.1. Mild Prevalent Cases (2016-2022)

5.5.2. Moderate Prevalent Cases (2016-2022)

5.5.3. Severe Prevalent Cases (2016-2022)

5.6. Prevalent Population in Spain (2016-2022)

5.6.1. Mild Prevalent Cases (2016-2022)

5.6.2. Moderate Prevalent Cases (2016-2022)

5.6.3. Severe Prevalent Cases (2016-2022)

5.7. Prevalent Population in United Kingdom (2016-2022)

5.7.1. Mild Prevalent Cases (2016-2022)

5.7.2. Moderate Prevalent Cases (2016-2022)

5.7.3. Severe Prevalent Cases (2016-2022)

5.8. Prevalent Population in Japan (2016-2022)

5.8.1. Mild Prevalent Cases (2016-2022)

5.8.2. Moderate Prevalent Cases (2016-2022)

5.8.3. Severe Prevalent Cases (2016-2022)

6. Current and Future Approaches of Care in Hemophilia A Treatment

6.1. Pre-replacement Therapy

6.2. Replacement Therapy

6.2.1. On Demand

6.2.2. Prophylaxis

6.3. Non-Replacement Therapy

6.3.1. Mimetics/Agonists

6.4. Gene Therapy

7. Marketed Drugs & Sales Forecast in Hemophilia A Treatment

7.1. CSL Behring: Afstyla (Antihemophilic Factor (Recombinant), Single Chain)

7.1.1. Product Profile

7.1.2. Safety & Efficacy

7.1.3. Afstyla Sales Forecast-2016-2022

7.2. Biogen IDEC: Eloctate [Antihemophilic Factor (Recombinant), Fc Fusion Protein]

7.2.1. Product Profile

7.2.2. Safety & Efficacy

7.2.3. Eloctate Sales Forecast-2016-2022

7.3. Genentech: Hemlibra (emicizumab-kxwh)

7.3.1. Product Profile

7.3.2. Safety & Efficacy

7.3.3. Hemlibra Sales Forecast-2016-2022

7.4. Bayer: Kogenate FS (Antihemophilic Factor Recombinant)

7.4.1. Product Profile

7.4.2. Safety & Efficacy

7.4.3. Kogenate FS Sales Forecast-2016-2022

7.5. Bayer: Kovaltry [Antihemophilic Factor (Recombinant)

7.5.1. Product Profile

7.5.2. Safety & Efficacy

7.5.3. Kovaltry Sales Forecast-2016-2022

7.6. Octapharma: Nuwiq (recombinant Factor VIII)

7.6.1. Product Profile

7.6.2. Safety & Efficacy

7.6.3. Nuwiq Sales Forecast-2016-2022

7.7. Shire (Baxter): Obizur [Antihemophilic Factor (Recombinant), Porcine Sequence]

7.7.1. Product Profile

7.7.2. Safety & Efficacy

7.7.3. Obizur Sales Forecast-2016-2022

8. Market Size & Forecast of Hemophilia A Treatment (2016-2022)

8.1. Market Forecast by Disease Care

8.1.1. Prophylaxis-Market Forecast (2016-2022)

8.1.2. On-demand therapy-Market Forecast (2016-2022)

8.1.3. Inhibitor therapy- Market Forecast (2016-2022)

8.2. Market Forecast by G7 Countries (2016-2022)

8.2.1. United States- Market Forecast (2016-2022)

8.2.2. Germany- Market Forecast (2016-2022)

8.2.3. France-Market Forecast (2016-2022)

8.2.4. Italy- Market Forecast (2016-2022)

8.2.5. Spain- Market Forecast (2016-2022)

8.2.6. United Kingdom- Market Forecast (2016-2022)

8.2.7. Japan- Market Forecast (2016-2022)

9. Factors Driving the Market of Hemophilia A Treatment

10. Factors Restraining the Market of Hemophilia A Treatment

11. About Research Cosmos Research

12. Disclaimer

13. Sales Support

Purchase this Market Research Report

REACH OUT TO US

Call us on : +1 888 709 8757

Drop us an email at : info@researchcosmos.com

HAVE A QUESTION?